Takeda and nference have formed a strategic research alliance to enhance the care of patients with inflammatory bowel disease (IBD), a chronic condition that affects millions worldwide. The alliance will utilize artificial intelligence to accomplish this. The objective of the collaboration, Project SUCCINCT, is to utilize nference's sophisticated machine learning models to analyze de-identified electronic health records. The initiative aims to enhance the outcomes of individuals with IBD by identifying patients who may benefit from advanced medical interventions and personalizing their treatment options. Takeda, a biopharmaceutical leader in gastroenterology, leverages its expertise in this partnership to enhance the diagnostic and treatment journey for IBD patients.
Introduced in 2021, nSights, nference's federated AI platform, is a critical component of this collaboration. The platform provides researchers with insights derived from an extensive, de-identified dataset encompassing various therapeutic areas, including gastroenterology. With access to data from over 40 million patient journeys across premier healthcare organizations, nference is well-positioned to advance research and AI model development. This partnership with Takeda reflects a shared commitment to pushing the boundaries of medical innovation, equipping healthcare providers to deliver more precise and timely treatments for patients with IBD.
